State-of-the-art production facility is opened by Takeda

By William O'Connor

Takeda Pharmaceutical Company Ltd, has officially opened a new cutting-edge manufacturing facility at its site at Grange Castle, Clondalkin. 

Marking the event on Friday (July 5), Minister for Employment Affairs and Social Protection, Regina Doherty, Takeda Pharmaceutical CEO Christophe Weber, H.E. Mrs Mari Miyoshi, Japanese Ambassador to Ireland, and Mary Buckley, Executive Director, IDA Ireland, joined 200 guests and staff for the opening celebration.

Takeda3 1

Paul Keogh (Grange Castle Plant Director, Takeda) with President and CEO of Takeda, Christophe Weber and Mary Buckley (Executive Director, IDA), Minister for Employment Affairs and Social Protection,

Regina Doherty TD and Thomas Wozniewski (Takeda Pharmaceutical’s Global Manufacturing & Supply Officer)Photo by Jason Clarke

Takeda has created this high containment, state-of-the-art production facility dedicated to the manufacturing of their oncology treatment.

Construction of the plant began in June 2017 and was managed by Project Management Group. A total of 40 jobs will be created at the site. 

The plant is the first Active Pharmaceutical Ingredient (API) manufacturing operation to be located outside of Japan for Takeda and houses all steps of the production process, including API, drug product and primary and secondary packaging for supply to global markets.

The Takeda Grange Castle plant currently employs over 80 people, all of whom are trained in the latest manufacturing techniques, to ensure operational excellence.

Commenting on the opening event, Takeda Pharmaceutical CEO Christophe Weber said: “I am delighted to be in Ireland for the official opening of our manufacturing site in Grange Castle. We have built up a strong foundation in Ireland over the past 17 years, and this new plant in Grange Castle is an important strategic site for us, as it is not only the first overseas manufacturing centre for APIs outside of Japan, but it houses all the steps of the production process.

"We are excited to take this next step and continue to deliver our medicines to patients around the world and concentrate our efforts on breakthrough innovations.

"I would like to thank our employees and stakeholders, as well as the IDA, for their support throughout the entire process.” 

Commenting on the opening event Mary Buckley, Executive Director, IDA Ireland said: “Manufacturing excellence in pharmaceuticals is a hallmark of Ireland's success in the sector.

"This innovative manufacturing site not only highlights Takeda’s commitment to Ireland, it also showcases how competitive Ireland is for global enterprise and investment.

"I wish Takeda continued success and on behalf of IDA Ireland offer our ongoing support.”

In addition to their oncology treatments, Takeda Ireland produces APIs for the treatment of diabetes, oncology, insomnia, weight loss, acid-related disease, bipolar disorder and hypertension. 

At the grand opening, Takeda also took the opportunity to introduce another project in Grange Castle to the public.

The company is investing about €30 million into a regenerative medicine facility at its site in Grange Castle, which will be the first commercial-scale cell-therapy production facility in Ireland.

This innovative facility will cover all steps of the cell-therapy production process from receipt of donor material to fill finish, packaging and shipment off site to the patient.

Prev C&C seeks inclusion in FTSE UK Index Series
Next Ireland’s heroines and where to find them

  • Double gold medal winner at the EYOF Rhasidat Adeleke receives a huge welcome home
  • ebeauty - Turquoise Glam
  • Rhasidat Adeleke strikes gold for second time at European Youth Olympics Festival
  • Tallaght Athletic Club's Rhasidat Adeleke speaking after winning gold
  • Tallaght Athletic Club's Rhasidat Adeleke wins gold

We use cookies to improve your experience on our site, personalise content, provide social media features, analyse our traffic, show you relevant advertising and to target and report on ads. By using the site, you consent to the use of cookies that may process personal data for these purposes.